Tags

Type your tag names separated by a space and hit enter

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population.
Depress Anxiety. 2008; 25(1):46-54.DA

Abstract

Escitalopram, the S-enantiomer of citalopram and the most selective of the selective serotonin reuptake inhibitor (SSRI) has been shown to be efficacious in the treatment of major depression in white populations. Our aim in this study was to investigate the efficacy and tolerability of escitalopram in Chinese patients with moderate to severe major depression. Patients who met DSM-IV criteria for a major depressive episode were enrolled in this multicenter, randomized, double-blind, fixed-dose comparison trial. Patients were given escitalopram 10 mg/day or fluoxetine 20 mg/day for 8 weeks. All patients were assessed with the 17-item Hamilton Depression Rating Scale (HAM-D-17) and the Montgomery-Asberg Depression Rating Scale (MADRS). Tolerability was assessed on the basis of adverse effects (measured with a locally developed checklist), regular biochemical tests, and electrocardiograph (ECG) assessments. Two hundred forty patients were enrolled and randomized to escitalopram (123 patients) or fluoxetine (117 patients). The HAM-D-17 total scores of both groups decreased significantly from baseline, but there was no significant difference at week 8 between the two groups (15.8 for escitalopram and 14.7 for fluoxetine; P >.05). There were no significant differences in response rates at all visits after treatment based on either HAM-D-17 or MADRS. A post hoc analysis indicated that escitalopram was superior to fluoxetine on two items of the HAM-D-17: "depressed mood" (P =.023) and "work and interest" (P =.024). The adverse events reported in the escitalopram and fluoxetine groups were comparable, and most were mild to moderate. Both drugs showed good compliance profiles. Escitalopram 10 mg/day is at least as efficacious as fluoxetine 20 mg/day and well tolerated in Chinese patients with major depression, with possible superiority in some core symptoms such as "depressed mood" and "work and interest."

Authors+Show Affiliations

Beijing Anding Hospital, Capital University of Medical Sciences, Beijing, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17149753

Citation

Mao, Pei-Xian, et al. "Escitalopram in Major Depressive Disorder: a Multicenter, Randomized, Double-blind, Fixed-dose, Parallel Trial in a Chinese Population." Depression and Anxiety, vol. 25, no. 1, 2008, pp. 46-54.
Mao PX, Tang YL, Jiang F, et al. Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. Depress Anxiety. 2008;25(1):46-54.
Mao, P. X., Tang, Y. L., Jiang, F., Shu, L., Gu, X., Li, M., Qian, M., Ma, C., Mitchell, P. B., & Cai, Z. J. (2008). Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. Depression and Anxiety, 25(1), 46-54.
Mao PX, et al. Escitalopram in Major Depressive Disorder: a Multicenter, Randomized, Double-blind, Fixed-dose, Parallel Trial in a Chinese Population. Depress Anxiety. 2008;25(1):46-54. PubMed PMID: 17149753.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. AU - Mao,Pei-Xian, AU - Tang,Yi-Lang, AU - Jiang,Feng, AU - Shu,Liang, AU - Gu,Xiuling, AU - Li,Ming, AU - Qian,Mincai, AU - Ma,Cui, AU - Mitchell,Philip B, AU - Cai,Zhuo-Ji, PY - 2006/12/7/pubmed PY - 2008/4/4/medline PY - 2006/12/7/entrez SP - 46 EP - 54 JF - Depression and anxiety JO - Depress Anxiety VL - 25 IS - 1 N2 - Escitalopram, the S-enantiomer of citalopram and the most selective of the selective serotonin reuptake inhibitor (SSRI) has been shown to be efficacious in the treatment of major depression in white populations. Our aim in this study was to investigate the efficacy and tolerability of escitalopram in Chinese patients with moderate to severe major depression. Patients who met DSM-IV criteria for a major depressive episode were enrolled in this multicenter, randomized, double-blind, fixed-dose comparison trial. Patients were given escitalopram 10 mg/day or fluoxetine 20 mg/day for 8 weeks. All patients were assessed with the 17-item Hamilton Depression Rating Scale (HAM-D-17) and the Montgomery-Asberg Depression Rating Scale (MADRS). Tolerability was assessed on the basis of adverse effects (measured with a locally developed checklist), regular biochemical tests, and electrocardiograph (ECG) assessments. Two hundred forty patients were enrolled and randomized to escitalopram (123 patients) or fluoxetine (117 patients). The HAM-D-17 total scores of both groups decreased significantly from baseline, but there was no significant difference at week 8 between the two groups (15.8 for escitalopram and 14.7 for fluoxetine; P >.05). There were no significant differences in response rates at all visits after treatment based on either HAM-D-17 or MADRS. A post hoc analysis indicated that escitalopram was superior to fluoxetine on two items of the HAM-D-17: "depressed mood" (P =.023) and "work and interest" (P =.024). The adverse events reported in the escitalopram and fluoxetine groups were comparable, and most were mild to moderate. Both drugs showed good compliance profiles. Escitalopram 10 mg/day is at least as efficacious as fluoxetine 20 mg/day and well tolerated in Chinese patients with major depression, with possible superiority in some core symptoms such as "depressed mood" and "work and interest." SN - 1091-4269 UR - https://www.unboundmedicine.com/medline/citation/17149753/Escitalopram_in_major_depressive_disorder:_a_multicenter_randomized_double_blind_fixed_dose_parallel_trial_in_a_Chinese_population_ L2 - https://doi.org/10.1002/da.20222 DB - PRIME DP - Unbound Medicine ER -